Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TRAIL R1 agonist
DRUG CLASS:
TRAIL R1 agonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
ABBV-621 (3)
CPT (0)
HLX56 (0)
AMG 951 (0)
HGS-ETR1 (0)
ABBV-621 (3)
CPT (0)
HLX56 (0)
AMG 951 (0)
HGS-ETR1 (0)
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
Phase 1
AbbVie
AbbVie
Completed
Phase 1
AbbVie
Completed
Last update posted :
12/09/2022
Initiation :
03/20/2017
Primary completion :
01/21/2022
Completion :
01/21/2022
KRAS
|
KRAS mutation • RAS mutation
|
Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection (NCT03083743)
Phase 3
Shanghai Gebaide Biotechnology Co., Ltd.
Shanghai Gebaide Biotechnology Co., Ltd.
Unknown status
Phase 3
Shanghai Gebaide Biotechnology Co., Ltd.
Unknown status
Last update posted :
03/20/2017
Initiation :
10/01/2016
Primary completion :
10/01/2017
Completion :
06/01/2018
ALK
|
EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative
|
dulanermin (AMG 951)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login